Download PDF
Thromb Haemost 2002; 88(04): 620-626
DOI: 10.1055/s-0037-1613265
Review Article
Schattauer GmbH

Anti-β2-glycoprotein I Antibody-mediated Inhibition of Activated Protein C Requires Binding of β2-glycoprotein I to Phospholipids

Tomonori Izumi   *
1   Division of Hematology, Departments of Medicine and Pathology, Duke University Medical Center, Durham, North Carolina, USA
,
Mary L. Pound
1   Division of Hematology, Departments of Medicine and Pathology, Duke University Medical Center, Durham, North Carolina, USA
,
Zuowei Su
1   Division of Hematology, Departments of Medicine and Pathology, Duke University Medical Center, Durham, North Carolina, USA
,
G. Michael Iverson
2   La Jolla Pharmaceutical Company, San Diego, California, USA
,
Thomas L. Ortel
1   Division of Hematology, Departments of Medicine and Pathology, Duke University Medical Center, Durham, North Carolina, USA
› Author AffiliationsThis work was supported by a grant-in-aid from the American Heart Association, Mid-Atlantic Affiliate (TLO), and a Midcareer Investigator Award in Patient-Oriented Research (K24 AIO1603-01) from the NIH (TLO). We thank Dr. Wayne F. Beyer, Department of Pathology, Duke University Medical Center, for amino acid sequencing and composition analyses of β2GPI, Mr. Keith F. Klemp for determination of patients’ genotypes, and Dr. Deborah A. Lewis for critically reviewing this manuscript.
Further Information

Publication History

Received 10 December 2001

Accepted after resubmission 03 June 2002

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

To clarify the role(s) of anti-β2GPI antibodies on thrombosis in antiphospholipid antibody syndromes (APS), the effect of IgG from three patients on activated protein C (APC) was investigated using phospholipid vesicles and purified proteins. Two of the total IgG inhibited APC activity in the presence of β2GPI, whereas the third IgG did not. In addition, one IgG inhibited APC activity without β2GPI. Anti-β2GPI IgG from the two inhibitory IgG preparations inhibited APC activity only in the presence of β2GPI. Inhibition was suppressed partially by excess APC and almost completely by excess phospholipid vesicles. Cleaved β2GPI, a non-phospholipid-binding form, did not support inhibitory activity, even though the anti-β2GPI IgG bound to the cleaved molecule. This study confirms that anti-β2GPI antibodies from APS patients inhibit APC activity, and demonstrates the requirement of phospholipid binding of β2GPI for expression of the inhibitory activity of these antibodies.

Keywords

Antiphospholipid antibody syndrome - β2-glycoprotein I - apolipoprotein H - activated protein C - phospholipid binding

* Present address: Division of Proteomics Research, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan


Presented in part at XVIIIth Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 6-12, 2001


 

  • References

  • 1 Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma ?2-glycoprotein I. Proc Natl Acad Sci USA 1984; 81: 3640-4.
    CrossrefPubMedGoogle Scholar
  • 2 Steinkasserer A, Estaller C, Weiss EH, Sim RB, Day AJ. Complete nucleotide and deduced amino acid sequence of human β2-glycoprotein I.. Biochem J 1991; 277: 387-91.
    CrossrefPubMedGoogle Scholar
  • 3 Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-5.
    CrossrefPubMedGoogle Scholar
  • 4 Ohkura N, Hagihara Y, Yoshimura T, Goto Y, Kato H. Plasmin can reduce the function of human β2 glycoprotein I by cleaving domain V into a nicked form. Blood 1998; 91: 4173-9.
    PubMedGoogle Scholar
  • 5 Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. β2-Glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. Thromb Haemost 1999; 81: 87-95.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Schousboe I. β2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-91.
    PubMedGoogle Scholar
  • 7 Nimpf J, Bevers EM, Bomans PH, Till U, Wurm H, Kostner GM, Zwaal RF. Prothrombinase activity of human platelets is inhibited by β2-glycoprotein-I. Biochim Biophys Acta 1986; 884: 142-9.
    CrossrefPubMedGoogle Scholar
  • 8 Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. β2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996; 75: 49-55.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Nimpf J, Wurm H, Kostner GM. Interaction of β2-glycoprotein-I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemost 1985; 54: 397-401.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Wurm H. β2-Glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511-5.
    CrossrefPubMedGoogle Scholar
  • 11 Chonn A, Semple SC, Cullis PR. β2-Glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of “non-self” particles. J Biol Chem 1995; 270: 25845-9.
    CrossrefPubMedGoogle Scholar
  • 12 Harper MF, Hayes PM, Lentz BR, Roubey RA. Characterization of β2-Glycoprotein I binding to phospholipid membranes. Thromb Haemost 1998; 80: 610-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
    CrossrefPubMedGoogle Scholar
  • 14 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32.
    PubMedGoogle Scholar
  • 16 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76: 101-7.
    CrossrefPubMedGoogle Scholar
  • 17 Matsuda J, Gotoh M, Gohchi K, Kawasugi K, Tsukamoto M, Saitoh N. Resistance to activated protein C activity of an anti-β2-glycoprotein I antibody in the presence of β2-glycoprotein I. Br J Haematol 1995; 90: 204-6.
    CrossrefPubMedGoogle Scholar
  • 18 Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
    CrossrefPubMedGoogle Scholar
  • 19 Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β2glycoprotein I. J Clin Invest 1992; 90: 1100-4.
    CrossrefPubMedGoogle Scholar
  • 20 Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, Ichikawa K, Koike T, Suzuki K. Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids. J Clin Invest 1997; 99: 2260-8.
    CrossrefPubMedGoogle Scholar
  • 21 Hunt J, Krilis S. The fifth domain of β2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653-9.
    PubMedGoogle Scholar
  • 22 Igarashi M, Matsuura E, Igarashi Y, Nagae H, Ichikawa K, Triplett DA, Koike T. Human β2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 1996; 87: 3262-70.
    PubMedGoogle Scholar
  • 23 George J, Gilburd B, Hojnik M, Levy Y, Langevitz P, Matsuura E, Koike T, Shoenfeld Y. Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β2GPI in antibody binding. J Immunol 1998; 160: 3917-23.
    PubMedGoogle Scholar
  • 24 Iverson GM, Victoria EJ, Marquis DM. Anti-?2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI. Proc Natl Acad Sci USA 1998; 95: 15542-6.
    CrossrefPubMedGoogle Scholar
  • 25 McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, Victoria EJ, Linnik MD. β2-Glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I. Thromb Haemost 2001; 86: 590-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Willems GM, Janssen MP, Pelsers MM, Comfurius P, Galli M, Zwaal RF, Bevers EM. Role of divalency in the high-affinity binding of anticardiolipin antibody-β2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
    CrossrefPubMedGoogle Scholar
  • 27 Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2glycoprotein I dependent lupus anticoagulants form stable bivalent antibody beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79: 79-86.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Polz E, Wurm H, Kostner GM. Investigations on β2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980; 11: 265-70.
    CrossrefPubMedGoogle Scholar
  • 29 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
    PubMedGoogle Scholar
  • 30 Higgins DL, Mann KG. The interaction of bovine factor V and factor Vderived peptides with phospholipid vesicles. J Biol Chem 1983; 258: 6503-8.
    PubMedGoogle Scholar
  • 31 Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, Koike T. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1466-74.
    CrossrefPubMedGoogle Scholar
  • 32 Galli M, Ruggeri L, Barbui T. Differential effects of anti-β2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 1999-2004.
    PubMedGoogle Scholar
  • 33 Ieko M, Ichikawa K, Triplett DA, Matsuura E, Atsumi T, Sawada K, Koike T. β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 1999; 42: 167-74.
    CrossrefPubMedGoogle Scholar
  • 34 Lutters BC, Meijers JC, Derksen RH, Arnout J, de Groot PG. Dimers of β2glycoprotein I mimic the in vitro effects of β2-glycoprotein I-anti-β2-glycoprotein I antibody complexes. J Biol Chem 2001; 276: 3060-7.
    CrossrefPubMedGoogle Scholar
  • 35 Smirnov MD, Ford DA, Esmon CT, Esmon NL. The effect of membrane composition on the hemostatic balance. Biochemistry 1999; 38: 3591-8.
    CrossrefPubMedGoogle Scholar
  • 36 Hansen KE, Kong DF, Moore KD, Ortel TL. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol 2001; 28: 2018-24.
    PubMedGoogle Scholar